$MOH
MOLINA HEALTHCARE, INC.

2012 Q4 Form 10-Q Financial Statement

#000119312512437608 Filed on October 26, 2012

View on sec.gov

Income Statement

Concept 2012 Q4 2012 Q3 2011 Q3
Revenue $1.578B $1.540B $1.177B
YoY Change 20.79% 30.88% 13.24%
Cost Of Revenue $1.319B $1.357B $993.7M
YoY Change 22.46% 36.56% 13.76%
Gross Profit $259.1M $183.2M $183.0M
YoY Change 12.9% 0.11% 10.51%
Gross Profit Margin 16.42% 11.89% 15.55%
Selling, General & Admin $191.1M $164.9M $136.0M
YoY Change 13.14% 21.25% 9.94%
% of Gross Profit 73.76% 90.01% 74.32%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization $20.50M $20.28M $17.81M
YoY Change -6.82% 13.85% 7.3%
% of Gross Profit 7.91% 11.07% 9.73%
Operating Expenses $207.3M $180.8M $149.5M
YoY Change 14.53% 20.94% 10.17%
Operating Profit $54.13M $2.368M $33.57M
YoY Change -436.17% -92.95% 12.26%
Interest Expense -$4.300M $4.315M $4.380M
YoY Change 10.26% -1.48% -195.22%
% of Operating Profit -7.94% 182.22% 13.05%
Other Income/Expense, Net $300.0K -$4.499M
YoY Change
Pretax Income $50.15M -$2.131M $29.19M
YoY Change -351.28% -107.3% 14.91%
Income Tax $21.60M -$1.966M $10.24M
% Of Pretax Income 43.07% 35.07%
Net Earnings $25.64M $3.364M $18.95M
YoY Change -177.8% -82.25% 16.98%
Net Earnings / Revenue 1.63% 0.22% 1.61%
Basic Earnings Per Share $0.55 $0.07 $0.41
Diluted Earnings Per Share $0.54 $0.07 $0.41
COMMON SHARES
Basic Shares Outstanding 46.58M shares 46.55M shares 45.83M shares
Diluted Shares Outstanding 46.88M shares 46.30M shares

Balance Sheet

Concept 2012 Q4 2012 Q3 2011 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $1.139B $1.072B $812.4M
YoY Change 37.07% 32.0% 30.65%
Cash & Equivalents $796.0M $715.5M $487.5M
Short-Term Investments $342.8M $356.9M $324.9M
Other Short-Term Assets $28.39M $30.00M $36.40M
YoY Change 46.06% -17.58% 10.98%
Inventory
Prepaid Expenses
Receivables $149.7M $156.9M $180.0M
Other Receivables $0.00 $33.50M $5.800M
Total Short-Term Assets $1.349B $1.314B $1.035B
YoY Change 28.72% 27.04% 17.18%
LONG-TERM ASSETS
Property, Plant & Equipment $221.4M $211.0M $127.7M
YoY Change 15.98% 65.21% 39.11%
Goodwill $151.1M $151.1M
YoY Change -1.86%
Intangibles
YoY Change
Long-Term Investments $13.40M $13.50M $18.10M
YoY Change 243.59% -25.41% -10.84%
Other Assets $19.62M $20.10M $117.3M
YoY Change 14.75% -82.87% 41.67%
Total Long-Term Assets $585.7M $592.7M $583.7M
YoY Change -3.04% 1.54% 6.42%
TOTAL ASSETS
Total Short-Term Assets $1.349B $1.314B $1.035B
Total Long-Term Assets $585.7M $592.7M $583.7M
Total Assets $1.935B $1.907B $1.618B
YoY Change 17.11% 17.84% 13.06%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $184.0M $151.0M $141.7M
YoY Change 25.0% 6.56% 20.8%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $1.155M $1.143M
YoY Change -3.51%
Total Short-Term Liabilities $828.0M $831.9M $604.4M
YoY Change 37.59% 37.65% 18.49%
LONG-TERM LIABILITIES
Long-Term Debt $261.8M $260.6M $168.1M
YoY Change 20.68% 55.0% 3.32%
Other Long-Term Liabilities $23.48M $22.10M $41.00M
YoY Change 7.8% -46.1% -7.03%
Total Long-Term Liabilities $285.3M $282.7M $209.1M
YoY Change 19.5% 35.18% 1.11%
TOTAL LIABILITIES
Total Short-Term Liabilities $828.0M $831.9M $604.4M
Total Long-Term Liabilities $285.3M $282.7M $209.1M
Total Liabilities $1.153B $1.152B $836.5M
YoY Change 28.47% 37.72% 14.01%
SHAREHOLDERS EQUITY
Retained Earnings $500.2M $474.6M
YoY Change 2.0%
Common Stock $285.5M $280.7M $260.2M
YoY Change 7.33% 7.9%
Preferred Stock
YoY Change
Treasury Stock (at cost) $3.000M
YoY Change
Treasury Stock Shares 111.0K shares
Shareholders Equity $782.3M $755.0M $781.8M
YoY Change
Total Liabilities & Shareholders Equity $1.935B $1.907B $1.618B
YoY Change 17.11% 17.84% 13.06%

Cashflow Statement

Concept 2012 Q4 2012 Q3 2011 Q3
OPERATING ACTIVITIES
Net Income $25.64M $3.364M $18.95M
YoY Change -177.8% -82.25% 16.98%
Depreciation, Depletion And Amortization $20.50M $20.28M $17.81M
YoY Change -6.82% 13.85% 7.3%
Cash From Operating Activities $83.80M $28.00M $40.30M
YoY Change 19.37% -30.52% -345.73%
INVESTING ACTIVITIES
Capital Expenditures -$25.60M -$19.20M -$15.00M
YoY Change 74.15% 28.0% 4.17%
Acquisitions
YoY Change
Other Investing Activities $22.80M -$10.20M $11.20M
YoY Change -122.89% -191.07% -205.66%
Cash From Investing Activities -$2.800M -$29.50M -$3.900M
YoY Change -97.55% 656.41% -84.4%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -700.0K -10.20M -8.100M
YoY Change -101.39% 25.93% -219.12%
NET CHANGE
Cash From Operating Activities 83.80M 28.00M 40.30M
Cash From Investing Activities -2.800M -29.50M -3.900M
Cash From Financing Activities -700.0K -10.20M -8.100M
Net Change In Cash 80.30M -11.70M 28.30M
YoY Change 1154.69% -141.34% -181.79%
FREE CASH FLOW
Cash From Operating Activities $83.80M $28.00M $40.30M
Capital Expenditures -$25.60M -$19.20M -$15.00M
Free Cash Flow $109.4M $47.20M $55.30M
YoY Change 28.86% -14.65% -2865.0%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2008Q1 us-gaap Available For Sale Securities
AvailableForSaleSecurities
82100000
CY2012Q2 moh Amount Of Damages Suffered
AmountOfDamagesSuffered
32600000
CY2011Q2 us-gaap Shares Outstanding
SharesOutstanding
46062000 shares
CY2012Q2 us-gaap Shares Outstanding
SharesOutstanding
46527000 shares
CY2012Q2 moh Liability For Claims And Claims Adjustment Expense Health
LiabilityForClaimsAndClaimsAdjustmentExpenseHealth
525538000
CY2012Q2 moh Number Of Membership For Temporary Assistance For Needy Families
NumberOfMembershipForTemporaryAssistanceForNeedyFamilies
79000 Customer
CY2011Q3 us-gaap Line Of Credit Facility Maximum Borrowing Capacity
LineOfCreditFacilityMaximumBorrowingCapacity
170000000
CY2011Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
487492000
CY2011Q3 us-gaap Debt Instrument Fair Value
DebtInstrumentFairValue
240649000
CY2011Q3 us-gaap Long Term Debt
LongTermDebt
218126000
CY2012Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
4571000
CY2012Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
370949
CY2012Q3 us-gaap Costs In Excess Of Billings On Uncompleted Contracts Or Programs Expected To Be Collected After One Year
CostsInExcessOfBillingsOnUncompletedContractsOrProgramsExpectedToBeCollectedAfterOneYear
67516000
CY2012Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
80000000 shares
CY2012Q3 us-gaap Other Assets Current
OtherAssetsCurrent
30002000
CY2012Q3 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
145510000
CY2012Q3 us-gaap Restricted Investments Noncurrent
RestrictedInvestmentsNoncurrent
44488000
CY2012Q3 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
10300000
CY2012Q3 us-gaap Held To Maturity Securities Debt Maturities After One Through Five Years Fair Value
HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
311000
CY2012Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000 shares
CY2012Q3 us-gaap Available For Sale Securities Debt Maturities After Ten Years Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost
14950000
CY2012Q3 us-gaap Available For Sale Securities Gross Unrealized Losses1
AvailableForSaleSecuritiesGrossUnrealizedLosses1
1557
CY2012Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-330000
CY2012Q3 us-gaap Liabilities Current
LiabilitiesCurrent
831936000
CY2012Q3 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
187000000
CY2012Q3 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
143301000
CY2012Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
474557000
CY2012Q3 us-gaap Assets
Assets
1907067000
CY2012Q3 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
370418000
CY2012Q3 us-gaap Availableforsale Securities Gross Unrealized Gain
AvailableforsaleSecuritiesGrossUnrealizedGain
1026
CY2012Q3 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Twelve Months Or Longer Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue
48
CY2012Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
715480000
CY2012Q3 us-gaap Income Tax Receivable
IncomeTaxReceivable
33530000
CY2012Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
151029000
CY2012Q3 us-gaap Debt Instrument Interest Rate Effective Percentage
DebtInstrumentInterestRateEffectivePercentage
0.075 pure
CY2012Q3 us-gaap Auction Rate Securities Noncurrent
AuctionRateSecuritiesNoncurrent
13523000
CY2012Q3 us-gaap Available For Sale Securities Debt Maturities After Ten Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue
13523000
CY2012Q3 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
146067000
CY2012Q3 us-gaap Availableforsale Securities Continuous Unrealized Loss Position12 Months Or Longer Aggregate Losses2
AvailableforsaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAggregateLosses2
17216
CY2012Q3 us-gaap Debt Instrument Fair Value
DebtInstrumentFairValue
296794000
CY2012Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
453070000 shares
CY2012Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
20098000
CY2012Q3 us-gaap Debt Instrument Convertible Carrying Amount Of The Equity Component
DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent
24000000
CY2012Q3 us-gaap Debt Instrument Convertible Conversion Price1
DebtInstrumentConvertibleConversionPrice1
31.29
CY2012Q3 us-gaap Line Of Credit Facility Amount Outstanding
LineOfCreditFacilityAmountOutstanding
40000000
CY2012Q3 us-gaap Deferred Tax Liabilities Noncurrent
DeferredTaxLiabilitiesNoncurrent
37478000
CY2012Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1907067000
CY2012Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
1109580 shares
CY2012Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2012Q3 us-gaap Held To Maturity Securities Debt Maturities Net Carrying Amount
HeldToMaturitySecuritiesDebtMaturitiesNetCarryingAmount
44488000
CY2012Q3 us-gaap Goodwill
Goodwill
151088000
CY2012Q3 us-gaap Liability For Claims And Claims Adjustment Expense
LiabilityForClaimsAndClaimsAdjustmentExpense
536463000
CY2012Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
438070000 shares
CY2012Q3 us-gaap Debt Instrument Interest Rate Stated Percentage
DebtInstrumentInterestRateStatedPercentage
0.0375 pure
CY2012Q3 us-gaap Derivative Instruments Not Designated As Hedging Instruments Liability At Fair Value
DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue
1270000
CY2012Q3 us-gaap Statutory Accounting Practices Statutory Capital And Surplus Required
StatutoryAccountingPracticesStatutoryCapitalAndSurplusRequired
270000000
CY2012Q3 us-gaap Liabilities
Liabilities
1152066000
CY2012Q3 us-gaap Available For Sale Securities Debt Maturities Within One Year Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
210489000
CY2012Q3 us-gaap Long Term Debt
LongTermDebt
261694000
CY2012Q3 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
13523000
CY2012Q3 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
173940000
CY2012Q3 us-gaap Deferred Tax Assets Net Current
DeferredTaxAssetsNetCurrent
21533000
CY2012Q3 us-gaap Availableforsale Securities Continuous Unrealized Loss Position Less Than12 Months Aggregate Losses2
AvailableforsaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAggregateLosses2
46782
CY2012Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
453070000 shares
CY2012Q3 us-gaap Held To Maturity Securities Debt Maturities Within One Year Fair Value
HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue
44186000
CY2012Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
23.45
CY2012Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2012Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2012Q3 us-gaap Preferred Stock Value
PreferredStockValue
CY2012Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
210972000
CY2012Q3 us-gaap Long Term Debt Current
LongTermDebtCurrent
1143000
CY2012Q3 us-gaap Held To Maturity Securities Debt Maturities Within One Year Net Carrying Amount
HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearNetCarryingAmount
44177000
CY2012Q3 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
210828000
CY2012Q3 us-gaap Amount Of Restricted Net Assets For Consolidated And Unconsolidated Subsidiaries
AmountOfRestrictedNetAssetsForConsolidatedAndUnconsolidatedSubsidiaries
519200000
CY2012Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
46571000 shares
CY2012Q3 us-gaap Unrecognized Tax Benefits That Would Impact Effective Tax Rate
UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
7200000
CY2012Q3 us-gaap Receivables Net Current
ReceivablesNetCurrent
156909000
CY2012Q3 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
356895000
CY2012Q3 us-gaap Common Stock Value Outstanding
CommonStockValueOutstanding
46000
CY2012Q3 us-gaap Available For Sale Securities Debt Maturities Without Single Maturity Date Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue
370418000
CY2012Q3 us-gaap Held To Maturity Securities Debt Maturities After One Through Five Years Net Carrying Amount
HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsNetCarryingAmount
311000
CY2012Q3 us-gaap Available For Sale Securities Debt Maturities Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesAmortizedCost
370949000
CY2012Q3 us-gaap Assets Current
AssetsCurrent
1314349000
CY2012Q3 us-gaap Significant Change In Unrecognized Tax Benefits Is Reasonably Possible Amount Of Unrecorded Benefit
SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit
8600000
CY2012Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
1966000
CY2012Q3 us-gaap Held To Maturity Securities Debt Maturities Fair Value
HeldToMaturitySecuritiesDebtMaturitiesFairValue
44497000
CY2012Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2012Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
260551000
CY2012Q3 us-gaap Statutory Accounting Practices Statutory Capital And Surplus Balance
StatutoryAccountingPracticesStatutoryCapitalAndSurplusBalance
525400000
CY2012Q3 us-gaap Available For Sale Securities Fair Value Disclosure
AvailableForSaleSecuritiesFairValueDisclosure
370418
CY2012Q3 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
59000
CY2012Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
280728000
CY2012Q3 us-gaap Stockholders Equity
StockholdersEquity
755001000
CY2012Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
85033000
CY2012Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
1966000
CY2012Q3 us-gaap Debt Instrument Unamortized Discount Premium Net
DebtInstrumentUnamortizedDiscountPremiumNet
13060000
CY2012Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
22101000
CY2012Q3 moh Goodwill And Intangible Assets Net
GoodwillAndIntangibleAssetsNet
236121000
CY2012Q3 moh Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageFairValue
21.78
CY2012Q3 moh Line Of Credit Facility Basis Spread On Federal Fund Rate
LineOfCreditFacilityBasisSpreadOnFederalFundRate
0.0050 pure
CY2012Q3 moh Line Of Credit Facility Basis Spread On Eurodollar Rate
LineOfCreditFacilityBasisSpreadOnEurodollarRate
0.0100 pure
CY2012Q3 moh Anticipated Medicare Risk Adjustment Premiums
AnticipatedMedicareRiskAdjustmentPremiums
1700000
CY2011Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
490410000
CY2012Q3 moh Available For Sale Securities In Unrealized Loss Position Twelve Months Or More Qualitative Disclosure Number Of Positions
AvailableForSaleSecuritiesInUnrealizedLossPositionTwelveMonthsOrMoreQualitativeDisclosureNumberOfPositions
1429 Security
CY2012Q3 moh Available For Sale Securities In Unrealized Loss Position Less Than Twelve Months Qualitative Disclosure Number Of Positions
AvailableForSaleSecuritiesInUnrealizedLossPositionLessThanTwelveMonthsQualitativeDisclosureNumberOfPositions
128 Security
CY2012Q3 moh Health Plans Segment Receivables
HealthPlansSegmentReceivables
124708000
CY2012Q3 moh Increase In Line Of Credit Facility Current Borrowing Capacity
IncreaseInLineOfCreditFacilityCurrentBorrowingCapacity
195000000
CY2012Q3 moh Liability For Claims And Claims Adjustment Expense Health
LiabilityForClaimsAndClaimsAdjustmentExpenseHealth
536463000
CY2012Q3 moh Line Of Credit Facility Debt Default Minimum Amount
LineOfCreditFacilityDebtDefaultMinimumAmount
20000000
CY2012Q3 moh Number Of Members Eligible For Health Care Programs
NumberOfMembersEligibleForHealthCarePrograms
1800000 Customer
CY2012Q3 moh Premium Deficiency Reserve
PremiumDeficiencyReserve
1500000
CY2012Q3 moh Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableInPeriodWeightedAverageGrantDateFairValue
21.33
CY2012Q3 moh Unrecognized Tax Benefits State Refund Claims
UnrecognizedTaxBenefitsStateRefundClaims
8400000
CY2012Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
46583300 shares
CY2010Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
455886000
CY2010Q4 us-gaap Shares Outstanding
SharesOutstanding
45463000 shares
CY2010Q4 moh Liability For Claims And Claims Adjustment Expense Health
LiabilityForClaimsAndClaimsAdjustmentExpenseHealth
354356000
CY2011Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
355317000
CY2011Q4 us-gaap Costs In Excess Of Billings On Uncompleted Contracts Or Programs Expected To Be Collected After One Year
CostsInExcessOfBillingsOnUncompletedContractsOrProgramsExpectedToBeCollectedAfterOneYear
54582000
CY2011Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
80000000 shares
CY2011Q4 us-gaap Other Assets Current
OtherAssetsCurrent
19435000
CY2011Q4 us-gaap Restricted Investments Noncurrent
RestrictedInvestmentsNoncurrent
46164000
CY2011Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
10700000
CY2011Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000 shares
CY2011Q4 us-gaap Available For Sale Securities Gross Unrealized Losses1
AvailableForSaleSecuritiesGrossUnrealizedLosses1
3108000
CY2011Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-1405000
CY2011Q4 us-gaap Liabilities Current
LiabilitiesCurrent
601834000
CY2011Q4 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
187000000
CY2011Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
50947000
CY2011Q4 us-gaap Assets
Assets
1652146000
CY2011Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
353050000
CY2011Q4 us-gaap Availableforsale Securities Gross Unrealized Gain
AvailableforsaleSecuritiesGrossUnrealizedGain
841000
CY2011Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Twelve Months Or Longer Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue
16134000
CY2011Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
493827000
CY2011Q4 us-gaap Income Tax Receivable
IncomeTaxReceivable
11679000
CY2011Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
147214000
CY2011Q4 us-gaap Auction Rate Securities Noncurrent
AuctionRateSecuritiesNoncurrent
16134000
CY2011Q4 us-gaap Availableforsale Securities Continuous Unrealized Loss Position12 Months Or Longer Aggregate Losses2
AvailableforsaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAggregateLosses2
2866000
CY2011Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
553049000 shares
CY2011Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
17099000
CY2011Q4 us-gaap Reinsurance Recoverables
ReinsuranceRecoverables
23401000
CY2011Q4 us-gaap Deferred Tax Liabilities Noncurrent
DeferredTaxLiabilitiesNoncurrent
33127000
CY2011Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1652146000
CY2011Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
1435882 shares
CY2011Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2011Q4 us-gaap Goodwill
Goodwill
153954000
CY2011Q4 us-gaap Liability For Claims And Claims Adjustment Expense
LiabilityForClaimsAndClaimsAdjustmentExpense
402476000
CY2011Q4 us-gaap Derivative Instruments Not Designated As Hedging Instruments Liability At Fair Value
DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue
CY2011Q4 us-gaap Liabilities
Liabilities
897073000
CY2011Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
16134000
CY2011Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
169526000
CY2011Q4 us-gaap Deferred Tax Assets Net Current
DeferredTaxAssetsNetCurrent
18327000
CY2011Q4 us-gaap Availableforsale Securities Continuous Unrealized Loss Position Less Than12 Months Aggregate Losses2
AvailableforsaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAggregateLosses2
242000
CY2011Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
18.97
CY2011Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2011Q4 us-gaap Reinsurance Payable
ReinsurancePayable
23401000
CY2011Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2011Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2011Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
190934000
CY2011Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
1197000
CY2011Q4 us-gaap Amount Of Restricted Net Assets For Consolidated And Unconsolidated Subsidiaries
AmountOfRestrictedNetAssetsForConsolidatedAndUnconsolidatedSubsidiaries
492400000
CY2011Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
45815000 shares
CY2011Q4 us-gaap Receivables Net Current
ReceivablesNetCurrent
167898000
CY2011Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
336916000
CY2011Q4 us-gaap Common Stock Value Outstanding
CommonStockValueOutstanding
46000
CY2011Q4 us-gaap Shares Outstanding
SharesOutstanding
45815000 shares
CY2011Q4 us-gaap Assets Current
AssetsCurrent
1048082000
CY2011Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2011Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
216929000
CY2011Q4 us-gaap Available For Sale Securities Fair Value Disclosure
AvailableForSaleSecuritiesFairValueDisclosure
353050000
CY2011Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
65000
CY2011Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue
96292000
CY2011Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
266022000
CY2011Q4 us-gaap Stockholders Equity
StockholdersEquity
755073000
CY2011Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
101796000
CY2011Q4 us-gaap Debt Instrument Unamortized Discount Premium Net
DebtInstrumentUnamortizedDiscountPremiumNet
17474000
CY2011Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
21782000
CY2011Q4 moh Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingIntrinsicValue
CY2011Q4 moh Goodwill And Intangible Assets Net
GoodwillAndIntangibleAssetsNet
255750000
CY2011Q4 moh Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageFairValue
20.91
CY2011Q4 moh Anticipated Medicare Risk Adjustment Premiums
AnticipatedMedicareRiskAdjustmentPremiums
5000000
CY2011Q4 moh Available For Sale Securities In Unrealized Loss Position Twelve Months Or More Qualitative Disclosure Number Of Positions
AvailableForSaleSecuritiesInUnrealizedLossPositionTwelveMonthsOrMoreQualitativeDisclosureNumberOfPositions
27 Security
CY2011Q4 moh Available For Sale Securities In Unrealized Loss Position Less Than Twelve Months Qualitative Disclosure Number Of Positions
AvailableForSaleSecuritiesInUnrealizedLossPositionLessThanTwelveMonthsQualitativeDisclosureNumberOfPositions
64 Security
CY2011Q4 moh Health Plans Segment Receivables
HealthPlansSegmentReceivables
121776000
CY2011Q4 moh Liability For Claims And Claims Adjustment Expense Health
LiabilityForClaimsAndClaimsAdjustmentExpenseHealth
402476000
moh Overestimated Period Of Run Out Claims
OverestimatedPeriodOfRunOutClaims
P90D
CY2011Q4 us-gaap Stock Repurchase Program Authorized Amount
StockRepurchaseProgramAuthorizedAmount
75000000
us-gaap Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
5259000
us-gaap Increase Decrease In Deferred Income Taxes
IncreaseDecreaseInDeferredIncomeTaxes
-8069000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
52414000
us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
3253000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-122662000
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
1125000
us-gaap Income Taxes Paid
IncomeTaxesPaid
43550000
us-gaap Technology Services Revenue
TechnologyServicesRevenue
111290000
us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
390000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
45693000 shares
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
25400000
us-gaap Stock Repurchased And Retired During Period Value
StockRepurchasedAndRetiredDuringPeriodValue
3751000
us-gaap Interest And Dividend Income Operating
InterestAndDividendIncomeOperating
3804000
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
84610000
us-gaap Policyholder Benefits And Claims Incurred Health Care
PolicyholderBenefitsAndClaimsIncurredHealthCare
2822049000
us-gaap Payments To Acquire Machinery And Equipment
PaymentsToAcquireMachineryAndEquipment
45921000
us-gaap Increase Decrease In Health Care Insurance Liabilities
IncreaseDecreaseInHealthCareInsuranceLiabilities
6699000
us-gaap Interest Paid
InterestPaid
5026000
us-gaap Share Based Compensation
ShareBasedCompensation
12723000
us-gaap Increase Decrease Of Restricted Investments
IncreaseDecreaseOfRestrictedInvestments
8394000
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
641000 shares
us-gaap Depreciation And Amortization
DepreciationAndAmortization
38587000
us-gaap Technology Services Costs
TechnologyServicesCosts
105020000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
31606000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
900000
us-gaap Payments To Acquire Projects
PaymentsToAcquireProjects
32765000
us-gaap Operating Income Loss
OperatingIncomeLoss
96276000
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.18
us-gaap Net Income Loss
NetIncomeLoss
53778000
us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
-5411000
us-gaap Costs And Expenses
CostsAndExpenses
3367256000
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.16
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
7000000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
290967000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
46334000 shares
us-gaap Increase Decrease In Other Noncurrent Assets And Liabilities Net
IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet
533000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-895000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
54208000
us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
-160000 shares
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1819000
us-gaap Interest Expense Debt
InterestExpenseDebt
9354000
us-gaap Revenues
Revenues
3463532000
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
4095000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
30832000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
430000
us-gaap Health Care Organization Premium Revenue
HealthCareOrganizationPremiumRevenue
3348438000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
5640000
us-gaap Proceeds From Long Term Lines Of Credit
ProceedsFromLongTermLinesOfCredit
60000000
us-gaap Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
5259000
us-gaap Increase Decrease In Deferred Income Taxes
IncreaseDecreaseInDeferredIncomeTaxes
-1166000
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
114229000 shares
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
246000
us-gaap Excess Tax Benefit From Share Based Compensation Financing Activities
ExcessTaxBenefitFromShareBasedCompensationFinancingActivities
1590000
us-gaap Weighted Average Number Of Shares Restricted Stock
WeightedAverageNumberOfSharesRestrictedStock
0 shares
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
226400000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
258209000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
12723000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
126000000 shares
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
226413000
us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
331000
us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
-5300000
us-gaap Interest Expense
InterestExpense
11666000
us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
-18957000
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
430000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
155163000
us-gaap Excess Tax Benefit From Share Based Compensation Operating Activities
ExcessTaxBenefitFromShareBasedCompensationOperatingActivities
647000
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
2451000
moh Amount Of Current Year Quality Incentive Premium Revenue Recognized
AmountOfCurrentYearQualityIncentivePremiumRevenueRecognized
9293000
moh Amount Of Quality Incentive Premium Revenue Recognized From Prior Year
AmountOfQualityIncentivePremiumRevenueRecognizedFromPriorYear
3865000
moh Benefit From Prior Period Claims Development
BenefitFromPriorPeriodClaimsDevelopment
49500000
moh Denominator For Diluted Earnings Per Share
DenominatorForDilutedEarningsPerShare
46334000 shares
moh Denominator For Basic Earnings Per Share
DenominatorForBasicEarningsPerShare
45693000 shares
moh Maximum Available Quality Incentive Premium Current Year
MaximumAvailableQualityIncentivePremiumCurrentYear
12036000
moh Payments For Medical Services Fees To Related Party
PaymentsForMedicalServicesFeesToRelatedParty
16800000
moh Premium Tax Expenses
PremiumTaxExpenses
110633000
moh Quality Incentive Premium Revenue Recognized
QualityIncentivePremiumRevenueRecognized
13158000
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2012
dei Document Type
DocumentType
10-Q
dei Document Period End Date
DocumentPeriodEndDate
2012-09-30
dei Entity Central Index Key
EntityCentralIndexKey
0001179929
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Trading Symbol
TradingSymbol
MOH
dei Entity Registrant Name
EntityRegistrantName
Molina Healthcare Inc
dei Amendment Flag
AmendmentFlag
false
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
58289000
us-gaap Availableforsale Securities Debt Maturities Date
AvailableforsaleSecuritiesDebtMaturitiesDate
2014-10-01
us-gaap Stock Repurchased And Retired During Period Value
StockRepurchasedAndRetiredDuringPeriodValue
9852000
us-gaap Interest And Dividend Income Operating
InterestAndDividendIncomeOperating
3996000
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-31081000
us-gaap Policyholder Benefits And Claims Incurred Health Care
PolicyholderBenefitsAndClaimsIncurredHealthCare
3823136000
us-gaap Payments To Acquire Machinery And Equipment
PaymentsToAcquireMachineryAndEquipment
52548000
us-gaap Increase Decrease In Health Care Insurance Liabilities
IncreaseDecreaseInHealthCareInsuranceLiabilities
133987000
us-gaap Interest Paid
InterestPaid
5663000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
1553000
us-gaap Business Combination Pro Forma Information Revenue Of Acquiree Since Acquisition Date Actual
BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual
38800000
us-gaap Share Based Compensation
ShareBasedCompensation
15448000
us-gaap Increase Decrease Of Restricted Investments
IncreaseDecreaseOfRestrictedInvestments
3034000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
47446000
us-gaap Technology Services Costs
TechnologyServicesCosts
98111000
us-gaap Supplemental Deferred Purchase Price
SupplementalDeferredPurchasePrice
2390000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
221653000
us-gaap Treasury Stock Shares Acquired
TreasuryStockSharesAcquired
0 shares
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
1400000
us-gaap Fair Value Of Assets Acquired
FairValueOfAssetsAcquired
30942000
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
2 Segment
us-gaap Gain Or Loss On Sale Of Stock In Subsidiary
GainOrLossOnSaleOfStockInSubsidiary
2390000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
92354000
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P3Y2M12D
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
846000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-90794000
us-gaap Income Taxes Paid
IncomeTaxesPaid
1074000
us-gaap Technology Services Revenue
TechnologyServicesRevenue
132351000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
31.86
us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
486000 shares
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y3M18D
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
46301000 shares
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Gain Loss Included In Other Comprehensive Income Loss
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss
-1439000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
20.47
us-gaap Payments To Acquire Projects
PaymentsToAcquireProjects
18799000
us-gaap Operating Income Loss
OperatingIncomeLoss
-18660000
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.34
us-gaap Proceeds From Divestiture Of Businesses And Interests In Affiliates
ProceedsFromDivestitureOfBusinessesAndInterestsInAffiliates
9162000
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P3Y4M24D
us-gaap Net Income Loss
NetIncomeLoss
-15853000
us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
-10989000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
15000000 shares
us-gaap Costs And Expenses
CostsAndExpenses
4468854000
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.34
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
379208000
us-gaap Operating Leases Income Statement Lease Revenue
OperatingLeasesIncomeStatementLeaseRevenue
5408000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
46301000 shares
us-gaap Increase Decrease In Other Noncurrent Assets And Liabilities Net
IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet
4775000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
48423000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
23.21
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-14778000
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
P3Y4M24D
us-gaap Repayments Of Long Term Lines Of Credit
RepaymentsOfLongTermLinesOfCredit
20000000
us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
744360 shares
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
10574000
us-gaap Interest Expense Debt
InterestExpenseDebt
9673000
us-gaap Revenues
Revenues
4450194000
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
4414000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-15228000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
1075000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
79999 shares
us-gaap Health Care Organization Premium Revenue
HealthCareOrganizationPremiumRevenue
4308439000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
498057 shares
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
5571000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-9030000
us-gaap Line Of Credit Facility Increase Additional Borrowings
LineOfCreditFacilityIncreaseAdditionalBorrowings
10300000
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Settlements
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements
4050000
us-gaap Stock Issued During Period Shares Share Based Compensation
StockIssuedDuringPeriodSharesShareBasedCompensation
755000 shares
us-gaap Excess Tax Benefit From Share Based Compensation Financing Activities
ExcessTaxBenefitFromShareBasedCompensationFinancingActivities
3698000
us-gaap Weighted Average Number Of Shares Restricted Stock
WeightedAverageNumberOfSharesRestrictedStock
0 shares
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
213700000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
750000 shares
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
234465000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
15448000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
0 shares
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
213665000
us-gaap Debt Instrument Interest Rate Terms
DebtInstrumentInterestRateTerms
The Eurodollar rate is a per annum rate of interest equal to the greater of (a) the rate that is published in the Wall Street Journal as the London interbank offered rate for deposits in United States dollars, for a period of one month, two business days prior to the commencement of an Interest Period, multiplied by a statutory reserve rate established by the Board of Governors of the Federal Reserve System, or (b) 4.25%.
us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
250000
us-gaap Liabilities Assumed1
LiabilitiesAssumed1
24170000
us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
-5166000
us-gaap Interest Expense
InterestExpense
12421000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
34.82
us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
-21878000
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
1075000
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Gain Loss Included In Earnings1
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1
903000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
14700000
us-gaap Availableforsale Securities Sold At Par
AvailableforsaleSecuritiesSoldAtPar
67100000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
264024000
us-gaap Derivative Instruments Not Designated As Hedging Instruments Gain Loss Net
DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
-1270000
us-gaap Debt Instrument Convertible Remaining Discount Amortization Period1
DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1
P24M
us-gaap Excess Tax Benefit From Share Based Compensation Operating Activities
ExcessTaxBenefitFromShareBasedCompensationOperatingActivities
159000
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
825000
moh Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue
moh Share Based Compensation Arrangement By Share Based Payment Award Options Forfeited In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodWeightedAverageGrantDateFairValue
22.37
moh Minimum Fixed Charge Coverage Ratio
MinimumFixedChargeCoverageRatio
1.75
moh Number Of Operating Reportable Segments
NumberOfOperatingReportableSegments
2 Segment
moh Amount Of Current Year Quality Incentive Premium Revenue Recognized
AmountOfCurrentYearQualityIncentivePremiumRevenueRecognized
38647000
moh Amount Of Quality Incentive Premium Revenue Recognized From Prior Year
AmountOfQualityIncentivePremiumRevenueRecognizedFromPriorYear
2116000
moh Area Covered By Property
AreaCoveredByProperty
460000 sqft
moh Benefit From Prior Period Claims Development
BenefitFromPriorPeriodClaimsDevelopment
37700000
moh Current Year Components Of Incurred Medical Care Costs
CurrentYearComponentsOfIncurredMedicalCareCosts
3860825000
moh Current Year Payments For Medical Care Costs
CurrentYearPaymentsForMedicalCareCosts
3332896000
moh Debt Instrument Convertible Number Of Equity Instruments Per One Thousand Principal Amount Of Debt
DebtInstrumentConvertibleNumberOfEquityInstrumentsPerOneThousandPrincipalAmountOfDebt
31.9601 pure
moh Denominator For Diluted Earnings Per Share
DenominatorForDilutedEarningsPerShare
46301000 shares
moh Denominator For Basic Earnings Per Share
DenominatorForBasicEarningsPerShare
46301000 shares
moh Line Of Credit Facility Description Variable Rate Basis
LineOfCreditFacilityDescriptionVariableRateBasis
The base rate is, for any day, a rate of interest per annum equal to the highest of (i) the prime rate of interest announced from time to time by U.S. Bank or its parent, (ii) the sum of the federal funds rate for such day plus 0.50% per annum and (iii) the Eurodollar rate (without giving effect to the applicable margin) for a one month interest period on such day (or if such day is not a business day, the immediately preceding business day) plus 1.00%.
moh Maximum Available Quality Incentive Premium Current Year
MaximumAvailableQualityIncentivePremiumCurrentYear
52869000
moh Maximum Contract Term
MaximumContractTerm
P4Y
moh Maximum Period For Member Risk Scores And Member Pharmacy Cost Experience After Original Year Of Service
MaximumPeriodForMemberRiskScoresAndMemberPharmacyCostExperienceAfterOriginalYearOfService
P2Y
moh Maximum Ratio Of Debt To Consolidated Earnings Before Interest Income Taxes Depreciation And Amortization Under Line Of Credit Facility Restrictive Covenants
MaximumRatioOfDebtToConsolidatedEarningsBeforeInterestIncomeTaxesDepreciationAndAmortizationUnderLineOfCreditFacilityRestrictiveCovenants
0.0275 pure
moh Minimum Contract Term
MinimumContractTerm
P3Y
moh Minimum Operating Revenue For Vesting Of Awards
MinimumOperatingRevenueForVestingOfAwards
5500000000
moh Number Of Categories For Component Of Premium Revenue
NumberOfCategoriesForComponentOfPremiumRevenue
2 pure
moh Par Value Of Auction Rate Securities Sold
ParValueOfAuctionRateSecuritiesSold
15000000
moh Payments For Medical Services Fees To Related Party
PaymentsForMedicalServicesFeesToRelatedParty
20600000
moh Payments For Medical Care Costs
PaymentsForMedicalCareCosts
3689149000
moh Percentage Of Premium Revenue
PercentageOfPremiumRevenue
0.293 pure
moh Period Of Termination Of Health Plan State Contract Notice Minimum
PeriodOfTerminationOfHealthPlanStateContractNoticeMinimum
P30D
moh Period Of Termination Of Health Plan State Contract Notice Maximum
PeriodOfTerminationOfHealthPlanStateContractNoticeMaximum
P9M
CY2011 moh Current Year Components Of Incurred Medical Care Costs
CurrentYearComponentsOfIncurredMedicalCareCosts
3911803000
CY2011 moh Current Year Payments For Medical Care Costs
CurrentYearPaymentsForMedicalCareCosts
3516994000
CY2011 moh Elimination Of Non Current Receivable And Liability Resulting From Sale Of Subsidiary
EliminationOfNonCurrentReceivableAndLiabilityResultingFromSaleOfSubsidiary
23400000
moh Policy Holder Benefits Prior Percentage
PolicyHolderBenefitsPriorPercentage
0.094 pure
moh Policy Holder Medical Care Cost Prior Year Percentage
PolicyHolderMedicalCareCostPriorYearPercentage
0.010 pure
moh Policy Holder Premium Revenue Prior Year Percentage
PolicyHolderPremiumRevenuePriorYearPercentage
0.009 pure
CY2011 moh Payments For Medical Care Costs
PaymentsForMedicalCareCosts
3811874000
CY2011 moh Policy Holder Benefits Prior Percentage
PolicyHolderBenefitsPriorPercentage
0.146 pure
moh Premium Tax Expenses
PremiumTaxExpenses
120953000
CY2011 moh Prior Year Components Of Incurred Medical Care Costs
PriorYearComponentsOfIncurredMedicalCareCosts
-51809000
CY2011Q3 us-gaap Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
1753000
CY2011Q3 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
17812000
CY2011Q3 us-gaap Technology Services Revenue
TechnologyServicesRevenue
37728000
CY2011Q3 us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
7000 shares
moh Prior Year Payments For Medical Care Costs
PriorYearPaymentsForMedicalCareCosts
356253000
moh Prior Year Components Of Incurred Medical Care Costs
PriorYearComponentsOfIncurredMedicalCareCosts
-37689000
moh Purchase Price For Acquisition Of Property
PurchasePriceForAcquisitionOfProperty
81000000
moh Quality Incentive Premium Revenue Recognized
QualityIncentivePremiumRevenueRecognized
40763000
moh Reinsurance Arrangement In Percentage
ReinsuranceArrangementInPercentage
1.00 pure
moh Share Based Compensation Arrangement By Share Based Payment Award Options Exercised In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodWeightedAverageGrantDateFairValue
19.29
moh Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageGrantDateFairValue
21.78
moh Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodIntrinsicValue
CY2012Q1 moh Payment Of Majority Of Claim Period
PaymentOfMajorityOfClaimPeriod
P4M
CY2011 us-gaap Policyholder Benefits And Claims Incurred Health Care
PolicyholderBenefitsAndClaimsIncurredHealthCare
3859994000
CY2011 moh Benefit From Prior Period Claims Development
BenefitFromPriorPeriodClaimsDevelopment
51800000
CY2011 moh Policy Holder Medical Care Cost Prior Year Percentage
PolicyHolderMedicalCareCostPriorYearPercentage
0.013 pure
CY2011 moh Policy Holder Premium Revenue Prior Year Percentage
PolicyHolderPremiumRevenuePriorYearPercentage
0.011 pure
CY2011 moh Prior Year Payments For Medical Care Costs
PriorYearPaymentsForMedicalCareCosts
294880000
CY2011Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
45834000 shares
CY2011Q3 us-gaap Interest And Dividend Income Operating
InterestAndDividendIncomeOperating
764000
CY2011Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
29186000
CY2011Q3 us-gaap Policyholder Benefits And Claims Incurred Health Care
PolicyholderBenefitsAndClaimsIncurredHealthCare
959158000
CY2011Q3 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
462000 shares
CY2011Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
13430000
CY2011Q3 us-gaap Technology Services Costs
TechnologyServicesCosts
34584000
CY2011Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
33566000
CY2011Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.41
CY2011Q3 us-gaap Net Income Loss
NetIncomeLoss
18950000
CY2011Q3 us-gaap Costs And Expenses
CostsAndExpenses
1143156000
CY2011Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.41
CY2011Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
99610000
CY2011Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
46296000 shares
CY2011Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
18785000
CY2011Q3 us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
-235000 shares
CY2011Q3 us-gaap Interest Expense Debt
InterestExpenseDebt
3137000
CY2011Q3 us-gaap Revenues
Revenues
1176722000
CY2011Q3 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
1384000
CY2011Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
10236000
CY2011Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-165000
CY2011Q3 us-gaap Health Care Organization Premium Revenue
HealthCareOrganizationPremiumRevenue
1138230000
CY2011Q3 us-gaap Weighted Average Number Of Shares Restricted Stock
WeightedAverageNumberOfSharesRestrictedStock
57000000 shares
CY2011Q3 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
105000000
CY2011Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4349000
CY2011Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
316000000 shares
CY2011Q3 us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
153000
CY2011Q3 us-gaap Interest Expense
InterestExpense
4380000
CY2011Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-165000
CY2011Q3 moh Amount Of Current Year Quality Incentive Premium Revenue Recognized
AmountOfCurrentYearQualityIncentivePremiumRevenueRecognized
2826000
CY2011Q3 moh Amount Of Quality Incentive Premium Revenue Recognized From Prior Year
AmountOfQualityIncentivePremiumRevenueRecognizedFromPriorYear
46000
CY2011Q3 moh Denominator For Diluted Earnings Per Share
DenominatorForDilutedEarningsPerShare
46296000 shares
CY2011Q3 moh Denominator For Basic Earnings Per Share
DenominatorForBasicEarningsPerShare
45834000 shares
CY2011Q3 moh Maximum Available Quality Incentive Premium Current Year
MaximumAvailableQualityIncentivePremiumCurrentYear
3546000
CY2011Q3 moh Payments For Medical Services Fees To Related Party
PaymentsForMedicalServicesFeesToRelatedParty
5000000
CY2011Q3 moh Premium Tax Expenses
PremiumTaxExpenses
36374000
CY2012Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
46546000 shares
CY2012Q3 us-gaap Interest And Dividend Income Operating
InterestAndDividendIncomeOperating
1171000
CY2012Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
2872000
CY2011Q3 moh Quality Incentive Premium Revenue Recognized
QualityIncentivePremiumRevenueRecognized
2872000
CY2012Q3 us-gaap Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
1753000
CY2012Q3 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
20279000
CY2012Q3 us-gaap Technology Services Revenue
TechnologyServicesRevenue
48422000
CY2012Q3 us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
19000 shares
CY2012Q3 us-gaap Policyholder Benefits And Claims Incurred Health Care
PolicyholderBenefitsAndClaimsIncurredHealthCare
1314571000
CY2012Q3 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
334000 shares
CY2012Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
16034000
CY2012Q3 us-gaap Technology Services Costs
TechnologyServicesCosts
37004000
CY2012Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
7187000
CY2012Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.07
CY2012Q3 us-gaap Net Income Loss
NetIncomeLoss
3364000
CY2012Q3 us-gaap Costs And Expenses
CostsAndExpenses
1533003000
CY2012Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.07
CY2012Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
127500000
CY2012Q3 us-gaap Operating Leases Income Statement Lease Revenue
OperatingLeasesIncomeStatementLeaseRevenue
1879000
CY2012Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
46880000 shares
CY2012Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
3819000
CY2012Q3 us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
shares
CY2012Q3 us-gaap Interest Expense Debt
InterestExpenseDebt
3252000
CY2012Q3 us-gaap Revenues
Revenues
1540190000
CY2012Q3 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
1499000
CY2012Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-492000
CY2012Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
455000
CY2012Q3 us-gaap Health Care Organization Premium Revenue
HealthCareOrganizationPremiumRevenue
1488718000
CY2012Q3 us-gaap Weighted Average Number Of Shares Restricted Stock
WeightedAverageNumberOfSharesRestrictedStock
370000000 shares
CY2012Q3 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
76800000
CY2012Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5636000
CY2012Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
125000000 shares
CY2012Q3 us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
12000
CY2012Q3 us-gaap Interest Expense
InterestExpense
4315000
CY2012Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
455000
CY2012Q3 moh Amount Of Current Year Quality Incentive Premium Revenue Recognized
AmountOfCurrentYearQualityIncentivePremiumRevenueRecognized
12397000
CY2012Q3 moh Amount Of Quality Incentive Premium Revenue Recognized From Prior Year
AmountOfQualityIncentivePremiumRevenueRecognizedFromPriorYear
246000
CY2012Q3 moh Benefit From Prior Period Claims Development
BenefitFromPriorPeriodClaimsDevelopment
47000000
CY2012Q3 moh Current Year Components Of Incurred Medical Care Costs
CurrentYearComponentsOfIncurredMedicalCareCosts
1361539000
CY2012Q3 moh Current Year Payments For Medical Care Costs
CurrentYearPaymentsForMedicalCareCosts
875236000
CY2012Q3 moh Denominator For Diluted Earnings Per Share
DenominatorForDilutedEarningsPerShare
46880000 shares
CY2012Q3 moh Denominator For Basic Earnings Per Share
DenominatorForBasicEarningsPerShare
46546000 shares
CY2012Q3 moh Maximum Available Quality Incentive Premium Current Year
MaximumAvailableQualityIncentivePremiumCurrentYear
21488000
CY2012Q3 moh Payments For Medical Services Fees To Related Party
PaymentsForMedicalServicesFeesToRelatedParty
7000000
CY2012Q3 moh Payments For Medical Care Costs
PaymentsForMedicalCareCosts
1303646000
CY2012Q3 moh Policy Holder Benefits Prior Percentage
PolicyHolderBenefitsPriorPercentage
0.089 pure
CY2012Q3 moh Policy Holder Medical Care Cost Prior Year Percentage
PolicyHolderMedicalCareCostPriorYearPercentage
0.036 pure
CY2012Q3 moh Policy Holder Premium Revenue Prior Year Percentage
PolicyHolderPremiumRevenuePriorYearPercentage
0.032 pure
CY2012Q3 moh Premium Tax Expenses
PremiumTaxExpenses
37894000
CY2012Q3 moh Prior Year Payments For Medical Care Costs
PriorYearPaymentsForMedicalCareCosts
428410000
CY2012Q3 moh Prior Year Components Of Incurred Medical Care Costs
PriorYearComponentsOfIncurredMedicalCareCosts
-46968000
CY2012Q3 moh Quality Incentive Premium Revenue Recognized
QualityIncentivePremiumRevenueRecognized
12643000

Files In Submission

Name View Source Status
0001193125-12-437608-index-headers.html Edgar Link pending
0001193125-12-437608-index.html Edgar Link pending
0001193125-12-437608.txt Edgar Link pending
0001193125-12-437608-xbrl.zip Edgar Link pending
d406541d10q.htm Edgar Link pending
d406541dex311.htm Edgar Link pending
d406541dex312.htm Edgar Link pending
d406541dex321.htm Edgar Link pending
d406541dex322.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
moh-20120930.xml Edgar Link completed
moh-20120930.xsd Edgar Link pending
moh-20120930_cal.xml Edgar Link unprocessable
moh-20120930_def.xml Edgar Link unprocessable
moh-20120930_lab.xml Edgar Link unprocessable
moh-20120930_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending